C15 (Pentadecanoic Acid)

C15 (Pentadecanoic Acid)'s downside is mainly uncertainty, opportunity cost, and poor fit in higher-risk situations. The same evidence that makes C15 (Pentadecanoic Acid) interesting also limits overconfidence: Sun et al. 2025 reports prospective and meta-analytic biomarker evidence and observational, not yet a C15:0 supplement trial. Risk tolerance should be lower for pregnancy, complex medical histories, prescription stacking, high-dose use, or chronic use without tracking. Wang et al. 2024 adds the caution lens because it reports preclinical pregnancy and developmental caution and preclinical supplement safety evidence. In practice, C15 (Pentadecanoic Acid) belongs in a simple protocol with one target, one review date, and a willingness to stop when the signal is weak.

Safety (Low): C15:0 safety sits at the 1.6-2.0 band for a real risk that is narrow, not at the benign floor, because Wang 2024 reports mild maternal glucose intolerance and offspring growth changes in mice, which is why the packet rules out pregnancy, lactation and near-term conception. No intrinsic life-threatening or permanently disabling event appears anywhere in the C15:0 packet, so SM-019 does not engage. SM-072 also does not engage: Robinson 2024 and Chooi 2024 are human trials with reported safety arms, which satisfies limb (a) of the human-safety-database test, so the absent-database aggravator carries no weight for C15:0.

Side effects (Negligible): C15:0 side effects sit in the 1.0-1.5 band of rare or mild complaints, the band that carries C15 as a written anchor. Across Robinson 2024 and Chooi 2024, 200 mg/day for twelve weeks produced no meaningful side-effect burden in a combined 118 participants. The honest limitation is power rather than a hidden signal: that sample cannot characterise uncommon effects, interactions or LDL responses, and the packet's uncontrolled user reports of occasional gastrointestinal complaints cannot serve as incidence estimates. Scored on what is documented for C15:0 at the studied dose, the profile is a low-grade nuisance risk and nothing more.

Cost premium (High): C15:0 cost sits in the 3.5-4.4 band, which the ladder anchors on C15 at forty dollars a month precisely because the same fatty acid is available from food. SM-007a defines this dimension as the premium over the cheapest legitimate route rather than the absolute price, and the packet prices the Fatty15 subscription at roughly forty to fifty dollars monthly while noting that grass-fed butter, aged cheese and full-fat yogurt deliver C15:0 alongside C17:0, butyrate, CLA, vitamin K2 and fat-soluble vitamins for less. A proprietary subscription with a far cheaper equivalent route is this band's definition.

Effort (Negligible): C15:0 effort sits in the 1.0-1.4 band for an action taking under a minute a day. The C15:0 protocol is one softgel with the largest fat-containing meal, with no device, session, preparation or timing constraint. The packet names a real but non-physical burden: managing an auto-ship subscription, deciding whether to buy the proprietary test bundle, and interpreting small biomarker changes without clinical thresholds. That is decision overhead rather than daily time, and the recommended twelve-week lab bracket adds two blood draws across a quarter. Against devices, exercise protocols and strict diets, C15:0 costs almost nothing in time.

Opportunity cost (High): C15:0 opportunity cost sits in the 3.1-5.0 band for a crowded category where several stronger validated options already dominate, the band the ladder anchors on C15 at 3.8. The packet makes the displacement concrete for every claimed lane: diet, weight loss, activity and clinician-guided care outrank C15:0 for fatty liver; LDL lowering, blood-pressure control, exercise, sleep, omega-3 and fiber outrank C15:0 for cardiovascular risk. The cost is attention as much as money, and the packet's own budget comparison sends the same forty dollars to vitamin D testing, omega-3, berberine or creatine ahead of C15:0.

Dependency (Negligible): C15:0 dependency sits at the 1.0-1.5 floor, the band that names C15 at 1.2, because the C15:0 packet describes no craving, no tolerance, no rebound physiology and no withdrawal syndrome. Stopping C15:0 returns circulating pentadecanoic acid toward baseline over weeks and nothing else happens. The packet calls the only dependency functional, meaning an elevated blood level requires ongoing intake, and the ladder is explicit that the benefit fading when a person stops belongs to Durability rather than here. A twelve-week C15:0 trial can be ended cleanly on the scheduled review date with no discontinuation management at all.

Reversibility (Negligible): C15:0 reversibility sits in the 1.0-1.3 band for full clearance with no named exception. The C15:0 packet records no permanent tissue change, irreversible enzyme inhibition, receptor remodeling or accumulation at 200 mg/day over twelve weeks, and plasma levels are expected to normalize within roughly four to eight weeks of stopping. Loss of the blood-level elevation on stopping is a Durability matter and is never counted here, and the unknown long-term picture is carried by Evidence and confidence rather than by this dimension. A C15:0 user can stop, retest labs later, and redirect the budget with no residue.